Portal de Periódicos da CAPES

Genetic variants in RhoA and ROCK1 genes are associated with the development, progression and prognosis of prostate cancer

2017; Impact Journals LLC; Volume: 8; Issue: 12 Linguagem: Inglês

10.18632/oncotarget.15197

1949-2553

Kang Liu, Xiao Li, Jie Wang, Yichun Wang, Huiyu Dong, Jie Li,

Genetic Associations and Epidemiology

// Kang Liu 1, * , Xiao Li 2, * , Jie Wang 1, * , Yichun Wang 1 , Huiyu Dong 1 , Jie Li 1, * 1 Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China 2 Department of Urology, The Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University, Nanjing, China * These authors contributed equally to this work Correspondence to: Jie Li, email: lijie_urology@163.com Keywords: genetic variants, RhoA/ROCK1 pathway, prostate cancer, prognosis, biochemical recurrence Received: July 27, 2016 Accepted: January 03, 2017 Published: February 08, 2017 ABSTRACT The contribution of genetic variants in RhoA and ROCK1 genes towards prostate cancer risk has not been reported before. We genotyped six potentially functional genetic variants in a case-control study of 1699 subjects. Overall, we found rs2410 mutant allele and rs2269736 wild allele were risk factors for prostate cancer. Individuals carrying more than two risk alleles were exposed to hazard of prostate cancer. In addition, we demonstrated that the risk of biochemical recurrence might be linked with clinico-pathological characteristics and also genetic factors. Unfortunately, no associations were observed between all polymorphisms and clinico-pathological characteristics. Moreover, no genotype was found as significant independent prognostic predictor for biochemical recurrence survival in Multivariate Cox regression analysis after Bonferroni correction. Our study is the first to clarify the relations of genetic variants of RhoA and ROCK1 genes with development, progression and prognosis of prostate cancer. These variants may be promising novel biomarkers to facilitate clinical treatment decision-making.